The FDA Panel Voted Yes on Six Peptides. Here Is What Actually Changed.

What happened, precisely.

On 23 and 24 July 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) met to consider whether seven peptide bulk drug substances should be added to the 503A Bulks List. That list defines which bulk substances a traditional compounding pharmacy may lawfully use when it prepares a customised medication for an identified patient.

The committee voted to recommend six of the seven: BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon. It declined to recommend the seventh, emideltide, the delta sleep-inducing peptide usually discussed as DSIP. Reporting on the meeting is consistent that the votes were close rather than decisive.

Two details matter more than the headline. First, FDA's own scientific reviewers had recommended against inclusion, writing that there was a lack of evidence to evaluate the effectiveness and safety of the specific peptides under review. The committee voted the other way. Second, PCAC is an advisory committee. Its recommendation is not an FDA decision.

What did not change: these peptides still cannot be lawfully compounded.

This is the part that marketing copy has comprehensively mangled, and it is worth stating flatly: as of this writing, none of these peptides can be lawfully compounded under section 503A.

A PCAC recommendation is an input to a process, not the end of one. FDA retains the authority to decide whether a substance is added to the Bulks List, and adding one happens through rulemaking, which takes time and can arrive at a different answer than the committee did. Between a favourable advisory vote and a pharmacy lawfully compounding a substance there are several steps, none of which have been completed.

So if you have seen a vendor or a clinic describe these compounds as newly 'FDA cleared', 'approved for compounding', or 'now legal', that claim is false. It was false the week the vote happened and it is still false now. The vote changed the regulatory conversation. It did not change what is legal.

Why a committee overruled the agency's own reviewers.

It is unusual enough to be worth sitting with. FDA staff reviewed the evidence packages and concluded they were insufficient to evaluate safety and effectiveness. The advisory committee, looking at the same material, voted to recommend six of the seven anyway.

That gap is not evidence that the peptides work. Advisory committees weigh several things at once, including clinical need, the reality that patients are already obtaining these substances from unregulated sources, and whether supervised compounding is preferable to an uncontrolled grey market. A vote can reflect a judgement about harm reduction and access rather than a judgement that the science is settled.

The honest reading is that the committee's recommendation tells you something about how the access question is being weighed, and close to nothing new about the underlying evidence. The evidence did not change in July 2026. The same trials, and the same absence of trials, sat in front of everyone in the room.

What this means for each compound.

On PepCue, none of these compounds moved on the evidence board because of the vote, and that is deliberate. Our tiers grade published human evidence. A regulatory committee's recommendation is not evidence, so it cannot move a grade.

BPC-157, TB-500 and MOTS-c all remain compounds where the mechanistic and preclinical literature substantially outweighs the human trial record. KPV is a short alpha-MSH fragment studied for inflammatory and wound-related activity, again largely preclinically. Semax and Epitalon have a Russian and post-Soviet clinical literature that is real but often not accessible, not replicated in Western trials, and difficult to appraise against contemporary standards. Emideltide, the compound the panel turned down, has the thinnest record of the group.

What did change is the regulatory section of each of these profiles, which now records the vote and the qualifier that has to travel with it. You can read the per-compound regulatory position at /legal/bpc-157 and the equivalent path for each of the others.

How to read the next twelve months.

A few things are worth watching, and a few are worth ignoring.

Worth watching: whether FDA initiates rulemaking on any of these substances, what the proposed rule says if it comes, and whether the agency's final position tracks its reviewers or its advisory committee. Also worth watching is whether any sponsor responds to the attention by actually running a well-powered human trial, which would do more for these compounds than any number of favourable votes.

Worth ignoring: vendor announcements timed to the vote, 'now compliant' labelling, and any framing that treats a recommendation as an approval. The reliable tell is whether a claim distinguishes between a recommendation, a rule, and an approval. Copy that blurs those three is not trying to inform you.

And the durable point underneath all of it: a compound's legal status and a compound's evidence base are two different axes. A substance can become lawful to compound while the human evidence for it stays thin, and plenty of substances with excellent evidence are tightly restricted. Conflating the two is the most common mistake in this category, and the July vote is about to generate a great deal of it.